Skip to main content

NCT00955279 - A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis

A Phase 2, Multicenter, Randomized, Double-Blind, Parallel-group, Placebo-controlled Study Evaluating the Safety and Efficacy of Treatment With Ustekinumab or Golimumab in Subjects With Chronic Sarcoidosis


CSR Summary

Not Yet Available


Data Specification

Not Yet Available


Annotated CRF

Not Yet Available

Product Info

Generic Name
Ustekinumab
Product Name
STELARA®
Therapeutic Area
Immune System Diseases
Enrollment
173
% Female
49.1%
% White
61.3%
Product Class
Antirheumatic Agents - Biologic Response Modifiers
Sponsor Protocol Number
1275148SCD2001
Data Partner
Johnson & Johnson
Condition Studied
Sarcoidosis
Mean/Median Age (Years)
49.8

Supporting Documentation

Clinical Study Report
Collected Datasets
Data Definition Specification
Annotated Case Report Form
Protocol with Amendments
Statistical Analysis Plan
Study Phase 
2

Disclaimer

Clinical study data provided through this site do not replace the official labeling of a given drug product, which presents benefits and risks of the product for approved use(s). Before prescribing any product, health care professionals should consult the current prescribing information approved in their country. Patients seeking information may consult with their health care professional about the product, for which health authority approved written patient information may be available.